Creating new male contraceptives using small molecule inhibitors
Official title: Development of small molecule inhibitors of RBM46 as novel male contraceptives
Funded at University of Texas San Antonio · NIH-11016997 · Data updated 2026-11-12
This study is exploring new ways for men to prevent pregnancy by targeting a protein important for sperm production, aiming to create a safe and easy-to-use non-hormonal contraceptive that can be reversed when desired.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas San Antonio NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $375,000 |
| NIH project number | 5R61HD114223-02 |
| Project ID | NIH-11016997 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research would be adult males who are seeking contraceptive options.
✕Less likely to help
Patients who are not male or those who do not wish to use male contraceptive methods may not receive any benefit from this research.
What this research studies
This research focuses on developing innovative male contraceptive methods by targeting a specific protein called RBM46, which is crucial for sperm production. The approach involves creating small molecules that can inhibit this protein, potentially leading to a safe and effective way to prevent pregnancy in men. The research aims to provide a non-hormonal contraceptive option that is reversible and easy to use. By combining expertise in drug development and male reproductive health, the project seeks to advance new contraceptive solutions to clinical application.
Why it matters
Potential benefit: If successful, this research could provide men with a reliable and reversible contraceptive option, helping to reduce unintended pregnancies.
How similar studies have gone: While the approach of targeting RBM46 is novel, previous research has shown promise in developing male contraceptives through similar mechanisms.
Where this research is happening
-
University of Texas San Antonio
San Antonio, United States Active
Researchers
- Principal investigator: Hermann, Brian Peter — University of Texas San Antonio
- Study coordinator: Hermann, Brian Peter
Related research
Other NIH-funded projects on the same topics.
-
Sex differences in brain injury biomarkers after repeated head impacts
This project looks at how sex hormones affect blood biomarkers after repeated head impacts, helping to understand why women may have different symptoms after brain injuries.
-
Auditory aging and serotonin: how mood-signaling chemicals influence hearing in older adults
A study will explore how the brain chemical serotonin affects hearing and brain circuits in aging, with the aim of helping older people understand speech in noisy settings.
-
Forced-dimer photoacoustic probes for deep tissue molecular imaging
A new type of dye-based sensor will detect molecular changes inside deep tissues using painless sound-based imaging instead of light alone.
-
How lipids and helper enzymes influence how TRP channels work
A study exploring how fat molecules and cellular helpers affect TRP ion channels that influence pain, diabetes, and heart conditions, with potential implications for safer pain treatment and cardiovascular health.
-
Molecular control of abnormal adult-born brain cells in epilepsy
Researchers are studying how new brain cells formed after a severe brain injury or seizure might contribute to epilepsy, with the goal of understanding how to prevent this mayhem in the hippocampus.
-
Turning harmful shoulder fat into healing beige fat with targeted nanomedicine
This project uses tiny medicine-filled nanoparticles to turn the harmful fat that builds up in torn shoulder muscles into healing, energy-burning fat to help people recover after rotator cuff tears.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.